Sun Pharmaceutical Industries
SUNPHARMA · Pharma · NSE
₹1,808
Current Market Price
Fair Value (DCF)
₹1,358
Discount to FV
-24.9%
Updated 14m ago
YieldIQ Score
53/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
50%
ROE
15.1%
Debt/Equity
0.03
WACC
9.5%
Market Cap
₹4.34 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
22.1%
Return on capital employed
EV / EBITDA
24.7×
Enterprise multiple
Debt / EBITDA
0.3×
Leverage vs earnings
Interest Coverage
45.6×
EBIT covers interest
Current Ratio
2.82×
Short-term liquidity
Asset Turnover
0.54×
Revenue per ₹ of assets
Revenue CAGR (3Y)
10.4%
3-year revenue growth
Revenue CAGR (5Y)
11.7%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,807.7
Bear case
Margin of Safety —
Implied upside -121.7%
Base case
Margin of Safety -49.5%
Implied upside -33.1%
Bull case
Margin of Safety +0.6%
Implied upside +0.6%
Ratio Trends
SUNPHARMA · last 8 annual periods
ROE
15.1%
ROCE
22.1%
Operating Margin
—
Debt / Equity
0.03×
PE
38.1×
EV / EBITDA
24.7×
Historical Financials
SUNPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹38.4K Cr | ₹43.3K Cr | ₹47.8K Cr | ₹52.0K Cr | ₹58.2K Cr | +10.9% |
| EBITDA | ₹6752 Cr | ₹12.1K Cr | ₹13.9K Cr | ₹16.6K Cr | ₹18.4K Cr | +28.5% |
| EBIT | ₹4609 Cr | ₹9580 Cr | ₹11.3K Cr | — | — | +25.2% |
| PAT | ₹3273 Cr | ₹8474 Cr | ₹9576 Cr | ₹10.9K Cr | ₹11.5K Cr | +36.9% |
| EPS (diluted) | ₹13.60 | ₹35.30 | ₹39.90 | — | — | +30.9% |
| CFO | ₹8985 Cr | ₹4959 Cr | ₹12.1K Cr | ₹14.1K Cr | ₹12.4K Cr | +8.4% |
| CapEx | ₹-1495 Cr | ₹-2086 Cr | ₹-2202 Cr | ₹-2129 Cr | ₹-3609 Cr | — |
| FCF | ₹7490 Cr | ₹2874 Cr | ₹9933 Cr | ₹11.9K Cr | ₹8810 Cr | +4.1% |
| Total Assets | ₹69.8K Cr | ₹80.7K Cr | ₹85.5K Cr | ₹92.1K Cr | ₹108.8K Cr | +11.7% |
| Total Debt | ₹1290 Cr | ₹6886 Cr | ₹3274 Cr | ₹2362 Cr | ₹4627 Cr | +37.6% |
| Shareholders' Equity | ₹48.0K Cr | ₹56.0K Cr | ₹63.7K Cr | ₹72.2K Cr | ₹83.6K Cr | +14.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SUNPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 DIVISLAB Divi's Laboratories Limited | -70.9%-41.5% upside | 40 | Data Limited | 15.3% | 0.7× |
 TORNTPHARM Torrent Pharmaceuticals Limited | -171.7%-63.2% upside | 40 | Above Fair Value | 25.8% | — |
 LUPIN Lupin Limited | +16.7%+20.1% upside | 52 | Below Fair Value | 23.8% | 19.8× |
 DRREDDY Dr. Reddy's Laboratories Limited | +8.9%+9.8% upside | 55 | Data Limited | 11.4% | 24.4× |
 CIPLA Cipla Limited | -7.8%-7.2% upside | 45 | Data Limited | 11.3% | 25.5× |
Click a ticker to view its fair-value analysis.
Dividend History
17 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹64.00/sh
Last payout
2026-02-05
₹11.00
Peak payout
₹11.00
Trailing yield
0.91%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Sun Pharmaceutical Industries (SUNPHARMA.NS) trades at 1807.70 vs a model fair value of 1357.90, a gap of -24.9%. Piotroski F-score: 6/9....
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SUNPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SUNPHARMA →
Compare
Head-to-head with peers
Compare SUNPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SUNPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.